Navigation Links
Takeda Completes Acquisition of Millennium
Date:5/14/2008

ll cease.

UBS Investment Bank acted as exclusive financial advisor and Edwards Angell Palmer & Dodge LLP acted as legal advisor to Takeda. Goldman, Sachs & Co. acted as exclusive financial advisor and WilmerHale acted as legal advisor to Millennium.

Cancellation of Millennium's 2008 Annual Meeting of Stockholders

Millennium also announced today that, as a result of its acquisition by Takeda, the 2008 annual meeting of stockholders, previously scheduled for Thursday, May 22, 2008, has been cancelled.

About Takeda

Founded in 1781 and located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.

About Millennium

Millennium, a Takeda Company, and a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Additional information about Millennium is available through its website, http:///www.millennium.com.

Forward-Looking Statements This press release contains "forward-looking statements" that involve significant risks and uncertainties. All statements other than statements of historical fact
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
2. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
3. Takeda Announces New U.S. Leadership
4. Takeda submits new drug application for alogliptin (syr-322) in the US
5. Chemizon Announces Research Collaboration Expansion With Takeda
6. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
7. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
8. InfoLogix Completes $25 Million Senior Debt Financing
9. ConforMIS Completes Executive Team With Addition of CFO
10. Facet Solutions, Inc. Completes Combination Facet Joint and Disc Replacement Study
11. Cardiva Medical, Inc. Completes $15.5 Million Private Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... -- Klafter & Olsen LLP has filed a,class action l..." or the,"Company") (Nasdaq: ARTC ) and certain o...Western District of Texas on behalf of all persons...Care from January 24, 2008,through July 18, 2008 (...,persons or entities who purchased call options or...
(Date:7/25/2008)...etroviral therapy may be due to genetic factors ,...new study challenges the long-held belief that the...,s ability to restore itself after HIV patients ar...y (HAART). , From 50 percent to 90 percent of H... Intravenous drug use is the main cause of both ty...
(Date:7/25/2008)...BeaconEquity.com announces the,availability of Tra... can view all of the daily trading notes for free ... Trade Alerts include: DUSA Pharmaceuticals Inc. (...(Nasdaq: MBRK ), NovaMed Inc. (Nasdaq:,NOVA), Ado...q: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX )., Joi...
(Date:7/25/2008)...ificant Improvements in Members, Health, ATLANTA,... in health,care quality management solutions for h...entered into a long-term agreement with Wellmark, ...on on Quality(SM) Incent and,Reward Best Practices...primary care clinicians to promote improved qualit...
Breaking Medicine News(10 mins):Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3
... so-called first world seems to be catching up fas...ity rates or sewage connection.// Only last fortn...t city in Ireland was reeling under a major water ...because of water contamination. Now the news come...
...ures from Canadian experts show that the country w...unless drastic measures are taken. Statistics Cana... heavily on immigration to plug the gaps left in, ...r legs. Says Statistics Canada: “An aging workfo...
...ng wire-free or Wi -Fi is fast becoming a more tha...needs of wires or the need to be connected to a so...ll primary schools and four fifths of all secondar...ere has been the rising of dissenting voices. Teac...
...tors in New York have achieved a major breakthroug...ladder through her vagina. // This technique, they...sual operation, and allow a quicker recovery. The ...d to cut through abdominal muscles, a major source...
Other Medicine News:Health News:Sewage Swamps River in Scotland 2Health News:Statisticians Alarmed As Canada Zooms Towards Labour Shortage 2Health News:Wire-Free – Handcuffing Good Healt 2Health News:New York Doctors Remove Gallbladder Through Vagina 2Health News:New York Doctors Remove Gallbladder Through Vagina 3
(Date:7/22/2008)...ility and Efficacy of Treating Patients with ...NCISCO, and YONGIN-SI, South Korea, July 22 /PRNew...tawa, Ontario), and its South,Korean partner Green...from,a Phase I clinical trial of its first-in-clas...t was well-tolerated and resulted in clear,anti-ca...
(Date:7/22/2008)...tress the Importance to Patients of Passing a ... RICHMOND, Va., July 22 /-...ow-on biologics and biopharmaceuticals, today,anno...ill present at a,Congressional briefing on Friday,...or establishing an approval pathway for follow-on,...
(Date:7/22/2008)... by Columbia University Medical Center Based on ...hnology, The Test Differentiates Squamous From N...lassifying Squamous-Cell Carcinoma of the Lung Wit... of 90 Percent,This is the First CLIA Approved Tes...as Biomarkers for Accurate Diagnosis of Lung Cance...
(Date:7/22/2008)...idual,s Genetic Risk Based on Clinical Data, Pr...al Materials, WALTHAM, Mass., July 22 /PRNewswire...ILI ), today announced the launch of an enhanced t...company,s Heart Health Genetic Test.,The test is c...Heart Health,Genetic Test by Quixtar/Amway. The ne...
Breaking Medicine Technology:Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Researchers successfully simulate photosynthesis and design a better leaf 1169 1Researchers successfully simulate photosynthesis and design a better leaf 1169 2Researchers successfully simulate photosynthesis and design a better leaf 1169 3Abnormal immune cells may cause unprovoked anaphylaxis 5990 1Abnormal immune cells may cause unprovoked anaphylaxis 5990 2Abnormal immune cells may cause unprovoked anaphylaxis 5990 3Research highlights important indicators of early stage ovarian cancer 5988 1New technology illuminates protein interactions in living cells 1167 1New technology illuminates protein interactions in living cells 1167 2
...ion Therapeutics,announced today that data on two ...prednate) and ST-602 (fenretinide), will be,presen...for,Research in Vision and Ophthalmology (ARVO) in...tions, the company will be hosting a,reception for...ntly being evaluated in two phase,III clinical tri...
...erlying Cause of,Genetic Disorders and Restores Pr...2007 /PRNewswire/ -- New,preclinical data publishe...ure show that PTC124, an investigational new drug,...ious in a,preclinical model of Duchenne muscular d... 13 percent of the cases of DMD are due,to nonsens...
Other Medicine Technology:Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 2Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 3Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 4Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 2Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 3Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 4
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability.
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability.
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability.
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available.
Medicine Products: